Skip to content
Learn More

Resources

iBio Announces Second COVID-19 Vaccine Program

June 4, 2020

IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for rapid manufacturing scale-up in iBio’s FastPharming SystemTM NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced initiation …

Read More

iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™

April 27, 2020

– Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals – NEW YORK , April 27, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today provided an update on its COVID-19 vaccine manufacturing capacity and announced that it …

Read More

iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute

April 9, 2020

– The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight – NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology innovator, today announced the signing of two Master Services Agreements (the MSAs”) and a Memorandum of Understanding (the “MoU”) …

Read More

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

March 27, 2020

NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint Development Agreement (the “MJDA”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).  Signed in 2018, the MJDA contemplates initial contract development and manufacturing of AzarGen’s …

Read More

iBio Announces Advancement of COVID-19 Vaccine Program

March 26, 2020

Preclinical Immunization Studies at Texas A&M University NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are proceeding at Texas A&M University System (“TAMUS”) laboratories. The work …

Read More
Top